oral anti-MRSA antibiotic
PreclinicalSmall molecule
oral anti-MRSA antibiotic is one of 15 small molecule programs targeting Staphylococcus aureus infection. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Staphylococcus Aureus Infection
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Dalvance
AbbVieApproved
Bactroban
PPadagis LLC
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Petrolatum
LEO PharmaApproved
Oritavancin
MMelinta Therapeutics, Inc.
Approved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oral anti-MRSA antibiotic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNatividad Medical Center